Mandate

Vinge has advised SBB in connection with the distribution of the shares in Neobo Fastigheter

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) in connection with the distribution of the shares in Neobo Fastigheter AB (publ) (”Neobo”) to the A and B shareholders in SBB. The resolution on the distribution was adopted at the Extraordinary General Meeting of SBB on 21 December 2022 and the distribution was carried out on 30 December 2022.

Neobo is a Swedish property company with its head office in Stockholm that long-term manages and refines rental properties in several locations in Sweden. The property portfolio is diversified over 40 municipalities with a total property value of SEK 15.8 billion. Residential properties account for 97 percent of the property portfolio’s market value and the remaining market value is made up of other properties.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, Joel Magnusson, Johannes Akyol, Gabriel Chabo, Clara Sohlberg, Kristoffer Larson, Albert Wållgren, Kamyar Najmi, Victor Ericsson and Maria Schultzberg.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025